• Je něco špatně v tomto záznamu ?

Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis

R. Hyšpler, A. Tichá, R. Šafránek, P. Moučka, Z. Nývltová, K. Štochlová, S. Dusilová-Sulková, Z. Zadák,

. 2018 ; 2018 (-) : 3985861. [pub] 20180815

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012398

Indoxyl sulfate has been identified as a major factor in the dysregulation of several genes. It is classified as a poorly dialyzable uremic toxin and thus a leading cause in the poor survival rate of dialysis patients. A monocentric, prospective, open cohort study was performed in 43 male patients undergoing chronic renal replacement therapy in a single hemodialysis center. The aim of the study was to determine the influence of acetate- versus citrate-buffered dialysis fluids in hemodialysis (HD) and postdilution hemodiafiltration (HDF) settings on the elimination of indoxyl sulfate. Also, additional factors potentially influencing the serum concentration of indoxyl sulfate were evaluated. For this purpose, the predialysis and postdialysis concentration ratio of indoxyl sulfate and total protein was determined. The difference was of 1.15 (0.61; 2.10), 0.89 (0.53; 1.66), 0.32 (0.07; 0.63), and 0.44 (0.27; 0.77) μmol/g in acetate HD and HDF and citrate HD and HDF, respectively. Acetate HD and HDF were superior when concerning IS elimination when compared to citrate HD and HDF. Moreover, residual diuresis was determined as the only predictor of lower indoxyl sulfate concentration, suggesting that it should be preserved as long as possible. This trial is registered with EU PAS Register of Studies EUPAS23714.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012398
003      
CZ-PrNML
005      
20231003094814.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2018/3985861 $2 doi
035    __
$a (PubMed)30186534
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hyšpler, Radomír $u Department of Clinical Biochemistry, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
245    10
$a Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis / $c R. Hyšpler, A. Tichá, R. Šafránek, P. Moučka, Z. Nývltová, K. Štochlová, S. Dusilová-Sulková, Z. Zadák,
520    9_
$a Indoxyl sulfate has been identified as a major factor in the dysregulation of several genes. It is classified as a poorly dialyzable uremic toxin and thus a leading cause in the poor survival rate of dialysis patients. A monocentric, prospective, open cohort study was performed in 43 male patients undergoing chronic renal replacement therapy in a single hemodialysis center. The aim of the study was to determine the influence of acetate- versus citrate-buffered dialysis fluids in hemodialysis (HD) and postdilution hemodiafiltration (HDF) settings on the elimination of indoxyl sulfate. Also, additional factors potentially influencing the serum concentration of indoxyl sulfate were evaluated. For this purpose, the predialysis and postdialysis concentration ratio of indoxyl sulfate and total protein was determined. The difference was of 1.15 (0.61; 2.10), 0.89 (0.53; 1.66), 0.32 (0.07; 0.63), and 0.44 (0.27; 0.77) μmol/g in acetate HD and HDF and citrate HD and HDF, respectively. Acetate HD and HDF were superior when concerning IS elimination when compared to citrate HD and HDF. Moreover, residual diuresis was determined as the only predictor of lower indoxyl sulfate concentration, suggesting that it should be preserved as long as possible. This trial is registered with EU PAS Register of Studies EUPAS23714.
650    _2
$a acetáty $x farmakologie $7 D000085
650    _2
$a senioři $7 D000368
650    _2
$a hydrogenuhličitany $7 D001639
650    _2
$a kyselina citronová $x krev $x farmakologie $7 D019343
650    _2
$a dialyzační roztoky $x chemie $x farmakologie $7 D015314
650    _2
$a hemodiafiltrace $x metody $7 D017583
650    _2
$a lidé $7 D006801
650    _2
$a indican $x krev $x farmakokinetika $7 D007200
650    _2
$a nemoci ledvin $x terapie $7 D007674
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a dialýza ledvin $x metody $7 D006435
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tichá, Alena $u Department of Clinical Biochemistry, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Šafránek, Roman $u Hemodialysis Centre, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Moučka, Petr $u Hemodialysis Centre, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Nývltová, Zora $u Vyzkumny Ustav Organickych Syntez A.S. (VUOS-Analytika), Rybitvi, Czech Republic. $7 xx0307711
700    1_
$a Štochlová, Karolína $u Vyzkumny Ustav Organickych Syntez A.S. (VUOS-Analytika), Rybitvi, Czech Republic.
700    1_
$a Dusilová-Sulková, Sylvie $u Hemodialysis Centre, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Zadák, Zdeněk $u Department of Clinical Biochemistry, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.
773    0_
$w MED00001413 $t Disease markers $x 1875-8630 $g Roč. 2018, č. - (2018), s. 3985861
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30186534 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20231003094811 $b ABA008
999    __
$a ok $b bmc $g 1391708 $s 1050703
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 2018 $c - $d 3985861 $e 20180815 $i 1875-8630 $m Disease markers $n Dis Markers $x MED00001413
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace